The article begins with the analysis of antiviral nature of Remdesivir, and analyzes its long journey as a new drug, simultaneously introduces its efficacy as a treatment for Ebola. At the same time, the article shows the core patents in China of Gilead Science, and answers the questions about the generic drugs related to Remdesivir that people are concerned about.

http://www.cncplt.com/Content/2020/02-04/1657290604.html

   LI, Ruifeng (Ralph)  CNPAT Lungtin IP Value Inc.    Project Director, Senior Patent Attorney, Associate Professor